Innovative Medicine

Revised prescribing information reflects FDA guidance to update labeling for all drugs within ESA class

Program Builds Prostate Cancer Awareness and Action in Support of America’s Veterans and Adds to Other Janssen Biotech Education Efforts for Men at High Risk, including Making Awareness a Priority (M.A.P.)

Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p Ibrutinib is an investigational oral Bruton’s tyrosine kinase inhibitor being studied in several B-cell malignancies

First Results of Collaboration Between Veridex, LLC and Massachusetts General Hospital Published in Science Translational Medicine

INVOKANA™ is the first in a new class of type 2 diabetes medications available in the United States In Phase 3 studies, INVOKANA™ improved blood glucose control and was associated with reductions in body weight and systolic blood pressure Janssen will partner with other Johnson & Johnson companies focused on diabetes to bring INVOKANA™ to healthcare professionals

Filing Based on Phase 3 Data in Treatment-Naïve and Treatment-Experienced Patients with Compensated Liver Disease

Program Further Extends XARELTO® as the Most Studied New Oral Anticoagulant in the World Today